NCT00000755View on ClinicalTrials.gov

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

PHASE1CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

Not specified

Study Completion Date

March 31, 1993

Conditions
HIV Infections
Interventions
BIOLOGICAL

rgp120/HIV-1MN

DRUG

Zidovudine

Trial Locations (10)

10016

NY Univ. HIV/AIDS CRS, New York

80262

University of Colorado Hospital CRS, Aurora

90095

UCLA CARE Center CRS, Los Angeles

941102859

Ucsf Aids Crs, San Francisco

943055107

Stanford CRS, Palo Alto

981224304

University of Washington AIDS CRS, Seattle

02114

Massachusetts General Hospital ACTG CRS, Boston

02118

Bmc Actg Crs, Boston

02215

Beth Israel Deaconess - East Campus A0102 CRS, Boston

Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Glaxo Wellcome

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000755 - A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3 | Biotech Hunter | Biotech Hunter